Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disorder of infancy and early childhood with an overproduction of myeloid cells that massively infiltrate hematopoietic and non-hematopoietic tissues. [1] [2] [3] JMML is characterized by 'spontaneous' proliferation of marrow and peripheral blood mononuclear cells in vitro with exuberant growth of granulo-macrophage colonies in the absence of exogenous growth factors, because of a selective hypersensitivity of the hematopoietic precursor cells to granulocyte macrophage colony-stimulating factor (GM-CSF). 4 Deregulation of GM-CSF signal transduction is driven by the RAS pathway because of oncogenic mutations in N-RAS, K-RAS, or PTPN11 genes or inactivation of the NF1 tumor suppressor gene. [5] [6] [7] GM-CSF-RAS pathway in turn affects signaling cascades downstream of GM-CSF receptor. 8 Multiparametric flow cytometric analysis has demonstrated new potentialities for assaying intracellular levels of phosphorylated proteins. 9 Here, we report the flow cytometric analysis of intracellular phosphorylated signal transducer and activator of transcription (pSTAT5) and evaluate the possible impact of our findings in the diagnostic work-up of JMML.
The study was approved by the Institutional Review Board and written informed consent was obtained from the parents of the patient's. Bone marrow samples were taken from three consecutive patients with a new diagnosis of JMML (biological and clinical characteristics at presentation are reported in (Table 1) and from 11 control patients (healthy donors for hematopoietic stem cell transplantation (HSCT) or patients with non-hematological malignancies). Bone marrow mononucleated cells were stimulated with escalating doses (from 0.01 to 10 ng/ml) of GM-CSF (PeproTech Inc., Offenbach, Germany) for 15 min at 37 1C to allow signal transduction. Cells were then fixed with paraformaldehyde (1.5%) and permeabilized with ice cold 90% methanol. The cells were then incubated with anti-phospho-STAT5 Alexa 488 (BD Biosciences, San Jose, CA, USA), surface anti-CD33 PE and anti-CD34 APC (BD Biosciences) antibodies and analyzed on a FACSaria flow cytometer (BD Biosciences) equipped with 488, 633 and 405 nm lasers. The pSTAT5 response to stimulation at each GM-CSF dose was calculated as either proportion (%) of pSTAT5-expressing cells or as log 2 of median fluorescence intensity stimulated/ median fluorescence intensity unstimulated. 9 The non-parametric Mann-Whitney U-test was used to determine the significance of differences among JMML and control patients. P-values less than 0.05 were considered statistically significant.
We examined in vitro response of bone marrow CD34 þ / CD33 þ JMML cells to escalating dose of exogenous GM-CSF. As shown in Figure 1a , CD34 þ /CD33 þ myeloid precursor cells demonstrated a greater increase in the proportion (%) of STAT5-phosphorylated cells in response to GM-CSF, as compared with the control cells. These differences were statistically significant at doses p1 ng/ml of GM-CSF (P-values from 0.011 to 0.035) and this finding was also confirmed by evaluating the pSTAT5 response in terms of median fluorescence intensity (P ¼ o0.05).
STAT5 is recruited to phosphorylated tyrosine residues on the activated GM-CSF receptor, indicating that STAT5 signaling profile reflects JMML hypersensitivity to GM-CSF. Our results are in agreement with those recently reported by Kotecha and colleagues 10 in CD38 intermediate-expressing cells from 10 JMML patients. In contrast to CD34 þ /CD33 þ cells, neither CD34À/CD33 þ (mature myeloid cells) nor CD34 þ /CD33À (non-myeloid precursors), demonstrated any STAT5 hyperphosphorylation in response to GM-CSF (data not shown). These results indicate that the peculiar STAT5 hyperphosphorylation signature specifically resides in the myeloid compartment of hematopoietic progenitor cells.
Currently, bone marrow transplantation represents the only therapy that demonstrated a clear impact on the outcome of JMML patients. 11 To assess whether this treatment modality may have an impact on STAT5 hyperphosphorylation signature, we analyzed the bone marrow mononucleated cells from two out of three patients at two time points after bone marrow transplantation (day 90 and day 120 in patient no. 1; day 21 and day 103 in patient no. 2). Both patients were in complete Recently, an allele-specific PCR assay (called TaqMAMA) has been proposed to track the most common mutations in PTPN11, K-RAS and N-RAS genes. Using this method, the authors demonstrated the possibility to quantify disease burden before HSCT and to measure minimal residual disease after HSCT in JMML patients. 12 In this context, upon confirmation and extension in larger series, flow cytometric monitoring of STAT5 phosphorylation signature may also represent a rapid and sensitive tool to evaluate response to therapy even in those patients without PTPN11 and RAS mutations.
In a previous study, Van Meter and colleagues 8 evaluated the consequences of expressing an oncogenic K-Ras G12D protein in hematopoietic cells of Mx1-Cre, LSL-Kras G12D mice. K-Ras G12D induced elevated levels of pSTAT5, pERK and pS6 in unstimulated c-kit þ lin À/low bone marrow stem/progenitor cells. It can be noted that, a higher percentage of Mx1-Cre, Kras G12D cells phosphorylated STAT5 in response to GM-CSF, but the magnitude and duration of STAT5 phosphorylation was similar in cells with both mutant and wild-type genotype. 8 We found that human myeloid progenitors bearing N-RAS mutation hyperphosphorylate STAT5 in terms of both magnitude of molecules and proportion of cells. Although our series is limited, the results show that human bone marrow CD34 þ / CD33 þ cells, but not CD34 þ /CD33À or CD34À/CD33 þ cells from JMML patients, represent the subset in which STAT5 hyperphosphorylation occurs in response to low doses of GM-CSF, and these observations were not reported earlier.
GM-CSF hypersensitivity has been reported in one case of congenital virus infections, showing a pattern between that of historical control and that seen in patients with JMML, 13 in addition, increased pSTAT3 and pSTAT5 expression have been recently described in polycythemia vera as well as in secondary forms of erythrocytosis and thrombocytosis.
14 These evidences suggest that either STAT5 hyperphosphorylation or GM-CSF hypersensitivity are not absolutely specific for JMML and their use for diagnostic purposes has to be considered in the context of an integrated approach. 4 In conclusion, our work further demonstrates that multiparametric flow cytometry is a rapid, sensitive and specific tool to study in detail signaling networks in primary cancer cells, and its application in JMML may represent a new integrated diagnostic tool. This novel and relatively simple approach could also give, in future studies, better insights into the genetic Letters to the Editor basis of hyper-responsiveness in primary human JMML, even providing a means of assessing the efficacy of emerging kinase inhibitors such as those blocking Ras/Raf or JAK2-signaling for the treatment of this disease.
